SEARCH

SEARCH BY CITATION

References

  • 1
    Mauskopf J. Prevalence-based economic evaluation. Value Health 1998;1:2519.
  • 2
    Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. Pharmacoeconomics 1999;16:44958.
  • 3
    Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 2000;18:5562.
  • 4
    Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:60921.
  • 5
    Koopmanshap MA, Ruttem FF. The drug budget silo mentality: the Dutch case. Value Health 2001;6(Suppl. 1):S4651.
  • 6
    Drummond M, Brown R, Fendrick AM, et al. ISPOR Task Force. Use of pharmacoeconomics information—report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003;6:40716.
  • 7
    Commonwealth Department of Health and Ageing. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, September 2002. Available from: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-general-pubs-guidelines-index.htm/$FILE/guidelines.pdf (Accessed August 2005).
  • 8
    Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 2nd edn. November 1997. Available from: http://www.ccohta.ca/publications/pdf/peg_e.pdf (Accessed August 2005).
  • 9
    Academy of Managed Care Pharmacy Format for Formulary Submissions. Version 2.1. April 2001. Available from: http://www.fmcpnet.org/data/resource/Format~Version_2_1~Final_Final.pdf (Accessed August 2005).
  • 10
    NHS. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal (reference N05515). 2004. Available from: http://www.nice.org.uk/pdf/TAP_Methods.pdf (Accessed August 2005).
  • 11
    Annemans L, Crott R, Degraeve D, et al. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Service 2002;24:57.
  • 12
    Collège des Economistes de la Santé. French Guidelines for Economic Evaluation of Health Care Technologies. September 2004. Available from: http://www.ispor.org/PEguidelines/source/France_Guidelines_HE_Evaluation.pdf (Accessed August 2005).
  • 13
    Szende A, Mogyorosy Z, Muszbek N, et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur J Health Econom 2002;3:196206.
  • 14
    Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J 2001;35:1892001.
  • 15
    Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004;7:110.
  • 16
    Guidelines for the Submission of a Request to Include a Pharmaceutical Product in the National List of Health Services. Version 4. April 2002. Available from: http://www.ispor.org/PEguidelines/source/PE%20GUIDELINES_Israel.pdf (Accessed September 10, 2006).
  • 17
    Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Future Drugs Ltd 2005;5:6579.
  • 18
    Simon GE, Von Korff M, Heligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs triciclic antidepressants. JAMA 1996;275:1897902.
  • 19
    Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. Manag Care Pharm 2000;9:1509.
  • 20
    Ozminkowski RJ, Wang S, Marder WD, et al. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeocnomics 2000;18:25364.
  • 21
    Grima DT, Burge RT, Beckr DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002;27:44855.
  • 22
    Nurnberg HG, Duttagupta S. Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. Am J Therapeutics 2003;11:912.
  • 23
    Mason JM, Moayyedi P, Young PJ, et al. Population-based and opportunistic screening and eradication ofHelicobacter pylori. Int J Tech Assess 1999;15:64960.
  • 24
    Mauskopf JA, Tolson JM, Simpson KN, et al. Impact of zidovudine-based triple combination therapy on an AIDS Drug Assistance Program. J Acquir Immune Defic Syndr 2000;23:30213.
  • 25
    Doyle JJ, Casciano J, Arikian S, et al. A multinational pharmacoeconomics evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs, and TCAs. Value Health 2001;4:1631.
  • 26
    Mauskopf JA. Meeting the NICE requirements: a Markov Model approach. Value Health 2000;3:28793.
  • 27
    Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management for arthritis in Canada. Pharmacoeconomics 2001;19(Suppl. 1):S4959.
  • 28
    Orlewska E. The cost-effectiveness of alternative therapeutic strategies for management of chronic hepatitis B in Poland. Value Health 2002;5:40420.
  • 29
    Mauskopf J, Muroff M, Gibson PJ, Grainger D. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 2002;28:61935.
  • 30
    Nuijten MJC, Rutten F. Combining a budgetary impact analysis and a cost-effectiveness analysis using decision analytic modeling techniques. Pharmacoeconomics 2002;20:85567.
  • 31
    Tavakoli M. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. Pharmacoeoconomics 2003;23:44354.
  • 32
    Dykstra DM, Beronja N, Menges J, et al. ESRD managed care demonstration: financial implications. Health Care Financ Rev 2003;24:5975.
  • 33
    Bigal ME, Rapoport AM, Bordini CA, et al. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 2003;43:74254.
  • 34
    Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003;64:295304.
  • 35
    Casciano J, Amaya K, Doyle J, et al. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care 2003;12:4754.
  • 36
    Sorensen J, Andersen LS. The case of Tumor Necrosis Factor-α inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. Pharmacoeconomics 2005;23:299314.
  • 37
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health care evaluation: report of the ISPOR Task Force on good research practices—modeling studies. Value Health 2003;6:917.
  • 38
    Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:52133.
  • 39
    Brosa M, Gisbert R, Rodríguez Barrios JM y Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en sanidad. Pharmacoeconomics Spanish Research Articles 2005;2:6579.